ConductScience.org, home

Paper39366135

Advancements in fourth-generation EGFR TKIs in EGFR-mutant NSCLC: Bridging biological insights and therapeutic development.

Corvaja C and 6 others. Cancer Treat Rev, 2024. Cited by 69 papers, by iCite.

Cite this record

ConductScience Library. Advancements in fourth-generation EGFR TKIs in EGFR-mutant NSCLC: Bridging biological insights and therapeutic development. Papers, record 39366135. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39366135

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Advancements in fourth-generation EGFR TKIs in EGFR-mutant NSCLC: Bridging biological insights and therapeutic development.
PubMed
Journal
Cancer Treat Rev
PubMed
Year
2024
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
69
iCite
Relative citation ratio, by iCite
9.52, provisional
iCite
Revised in PubMed
2026-01-27
PubMed

Authors7

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Corvaja CCarla
2Passaro AAntonio
3Attili IIlaria
4Aliaga PTPamela Trillo
5Spitaleri GGianluca
6Signore EDEster Del
7de Marinis FFilippo

Source PubMed

Download CSV of authors

Topics12

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
ErbB ReceptorsMajor topic
Carcinoma, Non-Small-Cell LungMajor topic
Lung NeoplasmsMajor topic
Protein Kinase InhibitorsMajor topic
MutationMajor topic
Humans
Aniline Compounds
Acrylamides
Drug Resistance, Neoplasm
Antineoplastic Agents
Indoles
Pyrimidines

Source PubMed

Download CSV of topics

Cited by56

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 69 citations.

PMIDTitleJournalYearIn PapersSource
42964587Overcoming adaptive resistance in non-small cell lung cancer: integrating targeted therapies, immunotherapy synergy, and nanocarrier delivery.Front Pharmacol2026https://conductscience.org/library/papers/42964587PubMed
42919317ERK/GATAD2A/SAA1 axis drives osimertinib resistance via NF-κB and macrophage reprogramming in EGFR-mutated lung adenocarcinoma.J Exp Clin Cancer Res2026https://conductscience.org/library/papers/42919317PubMed
42917883A Structural Perspective on Non-covalent Targeting of Conserved Polar Residues in Protein Kinases.J Med Chem2026https://conductscience.org/library/papers/42917883PubMed
42891869
Effectiveness of local ablative therapy combined with first-line tyrosine kinase inhibitors in epidermal growth factor receptor-mutated oligometastatic non-small cell lung cancer: a systematic review and meta-analysis.
Clin Exp Metastasis2026https://conductscience.org/library/papers/42891869PubMed
42827960Oral mucositis risk with EGFR tyrosine kinase inhibitor monotherapies and combination regimens in non-small cell lung cancer: a systematic review and network meta-analysis.Front Immunol2026https://conductscience.org/library/papers/42827960PubMed
42757482A four‑gene signature identifies TKI‑induced persister cells and uncovers a ZLN005‑induced pyroptotic vulnerability via the GSDME pathway in EGFR‑mutant lung cancer.Mol Med Rep2026https://conductscience.org/library/papers/42757482PubMed
42729980Resistance to third-generation EGFR TKIs - what can be expected from the fourth-generation?Cancer Drug Resist2026https://conductscience.org/library/papers/42729980PubMed
42639301Immune checkpoint inhibitor-based combinatory and alternative strategies for immune treatment of lung cancers.Front Immunol2026https://conductscience.org/library/papers/42639301PubMed
42588669Targeting EGFR Endocytosis and Signaling for Cancer Drug Delivery and Cancer Treatment.Cancers (Basel)2026https://conductscience.org/library/papers/42588669PubMed
42536589Baseline predictors of early progression during EGFR-TKI therapy in patients with EGFR-mutant non-small cell lung cancer: A retrospective cohort study.Medicine (Baltimore)2026https://conductscience.org/library/papers/42536589PubMed
42519174ColdstartMHDTI: integrating biomolecular pretraining and attention-based heterogeneous graph learning for drug-target interaction prediction.Front Chem2026https://conductscience.org/library/papers/42519174PubMed
42463770Multiparatopic antibodies overcome tyrosine kinase inhibitor resistance by inducing lysosomal degradation of EGFR mutants.Oncogene2026https://conductscience.org/library/papers/42463770PubMed
42440354Osimertinib plus Gefitinib in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer and EGFR (C797X) Mutation Following First-Line Osimertinib: ORCHARD.Clin Cancer Res2026https://conductscience.org/library/papers/42440354PubMed
42436136Specimen quality shapes the actionable genomic landscape in comprehensive cancer genomic profiling.NPJ Genom Med2026https://conductscience.org/library/papers/42436136PubMed
42334959Recent progress in cancer multidrug resistance and therapeutic options associated with protein damage response.Protein Cell2026https://conductscience.org/library/papers/42334959PubMed
42260055Pigmentary Changes Reported with Tyrosine Kinase Inhibitors: A Narrative Review of Mechanisms and Clinical Implications.Clin Drug Investig2026https://conductscience.org/library/papers/42260055PubMed
42179048Design and Pictet-Spengler enabled synthesis of carboxamide-substituted imidazo[1,2-a]quinoxalines as dual EGFR and tubulin targeting anticancer agents.J Enzyme Inhib Med Chem2026https://conductscience.org/library/papers/42179048PubMed
42106797CASK promotes non-small cell lung cancer growth through coordinated regulation of EGFR expression, trafficking, and p21 expression.J Biomed Sci2026https://conductscience.org/library/papers/42106797PubMed
421026924-Anilinoquinazoline carbamate derivatization as a platform for prodrug design and localized drug delivery.Bioorg Chem2026https://conductscience.org/library/papers/42102692PubMed
41976235Molecularly Targeted Therapies in Oncology: Mechanisms, Resistance, and Combination Strategies.Molecules2026https://conductscience.org/library/papers/41976235PubMed

See all 56 cited byDownload CSV of cited by

Genes3

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
EGFR1956PubTator's text mininghttps://conductscience.org/library/genes/1956NCBI Gene
ERBB22064PubTator's text mininghttps://conductscience.org/library/genes/2064NCBI Gene
SLTM79811PubTator's text mininghttps://conductscience.org/library/genes/79811NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39366135

GET https://conductscience.org/api/papers/v1/39366135/cited_by?page=2